Skip to main content
SpringerLink
Log in

Cytokines and Chemokines

  • Chapter
  • First Online:
Neuropsychiatric Systemic Lupus Erythematosus

  • 594 Accesses

Abstract

Neuropsychiatric syndromes of systemic lupus erythematosus (NPSLE) is a life-threatening disorder and early diagnosis and proper treatment are critical for the management of patients with this disease. Brain magnetic resonance imaging, electroencephalogram, neuropsychological tests and routine cerebrospinal fluid (CSF) examination are used clinically for the diagnosis of NPSLE. In addition to these tests, cytokine and chemokine levels in the CSF have been reported as useful diagnostic markers of NPSLE. This chapter provides an overview of the roles of cytokines and chemokines in NPSLE.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature. Arthritis Rheum. 1999; 42:599–608.

    Google Scholar 

  2. Bresnihan B. CNS lupus. Clin Rheum Dis. 1982;8:183–95.

    CAS  PubMed  Google Scholar 

  3. Brey RL, et al. Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology. 2002;58:1214–20.

    Article  CAS  PubMed  Google Scholar 

  4. Ainiala H, et al. The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology. 2001;57:496–500.

    Article  CAS  PubMed  Google Scholar 

  5. Trysberg E, et al. Intrathecal cytokines in systemic lupus erythematosus with central nervous system involvement. Lupus. 2000;9:498–503.

    Article  CAS  PubMed  Google Scholar 

  6. Svenungsson E, et al. Increased levels of proinflammatory cytokines and nitric oxide metabolites in neuropsychiatric lupus erythematosus. Ann Rheum Dis. 2001;60:372–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Iikuni N, et al. Raised monocyte chemotactic protein-1 (MCP-1)/CCL2 in cerebrospinal fluid of patients with neuropsychiatric lupus. Ann Rheum Dis. 2006;65:253–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Okamoto H, et al. IP-10/MCP-1 ratio in CSF is a useful diagnostic marker of neuropsychiatric lupus patients. Rheumatology. 2006;45:232–4.

    Article  CAS  PubMed  Google Scholar 

  9. Okamoto H, et al. Interferon-inducible protein 10/CXCL10 is increased in the cerebrospinal fluid of patients with central nervous system lupus. Arthritis Rheum. 2004;50:3731–2.

    Article  CAS  PubMed  Google Scholar 

  10. Yoshio T, et al. IL-6, IL-8, IP-10, MCP-1 and C-CSF are significantly increased in cerebrospinal fluid but not in sera of patients with central neuropsychiatric lupus erythematosus. Lupus. 2016;25:997–1003.

    Article  CAS  PubMed  Google Scholar 

  11. Alcocer-Varela J, et al. Interleukin-1 and interleukin-6 activities are increased in the cerebrospinal fluid of patients with CNS lupus erythematosus and correlate with local late T-cell activation markers. Lupus. 1992;1:111–7.

    Article  CAS  PubMed  Google Scholar 

  12. Gilad R, et al. Cerebrospinal fluid soluble interleukin-2 receptor in cerebral lupus. Br J Rheumatol. 1997;36:190–3.

    Article  CAS  PubMed  Google Scholar 

  13. Jönsen A, et al. The heterogeneity of neuropsychiatric systemic lupus erythematosus is reflected in lack of association with cerebrospinal fluid cytokine profiles. Lupus. 2003;12:846–50.

    Article  PubMed  Google Scholar 

  14. Jara LJ, et al. Prolactin and interleukin-6 in neuropsychiatric lupus erythematosus. Clin Rheumatol. 1998;17:110–4.

    Article  CAS  PubMed  Google Scholar 

  15. Hirohata S, Miyamoto T. Elevated levels of interleukin-6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous system involvement. Arthritis Rheum. 1990;33:644–9.

    Article  CAS  PubMed  Google Scholar 

  16. Hirohata S, Hayakawa K. Enhanced interleukin-6 messenger RNA expression by neuronal cells in a patient with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 1999;42:2729–30.

    Article  CAS  PubMed  Google Scholar 

  17. Tsai CY, et al. Cerebrospinal fluid interleukin-6, prostaglandin E2 and autoantibodies in patientswith neuropsychiatric systemic lupus erythematosus and central nervous system infections. Scand J Rheumatol. 1994;23:57–63.

    Article  CAS  PubMed  Google Scholar 

  18. Dellalibera-Joviliano R, et al. Kinins and cytokines in plasma and cerebrospinal fluid of patients with neuropsychiatric lupus. J Rheumatol. 2003;30:485–92.

    CAS  PubMed  Google Scholar 

  19. Fragoso-Loyo H, et al. Interleukin-6 and chemokines in the neuropsychiatric manifestations of systemic lupus erythematosus. Arthritis Rheum. 2007;56:1242–50.

    Article  CAS  PubMed  Google Scholar 

  20. Winfield JB, et al. IntrathecalIgG synthesis and blood-brain barrier impairment in patients with systemic lupus erythematosus and central nervous system dysfunction. Am J Med. 1983;74:837–44.

    Article  CAS  PubMed  Google Scholar 

  21. Shiozawa S, et al. Interferon-alpha in lupus psychosis. Arthritis Rheum. 1992;35:417–22.

    Article  CAS  PubMed  Google Scholar 

  22. Aringer M, et al. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum. 2004;50:3161–9.

    Article  CAS  PubMed  Google Scholar 

  23. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med. 2008;358:929–39.

    Article  CAS  PubMed  Google Scholar 

  24. Santer DM, et al. Potent induction of IFN-alpha and chemokines by autoantibodies in the cerebrospinal fluid of patients with neuropsychiatric lupus. J Immunol. 2009;182:1192–201.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Wichers M, Maes M. The Psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. Int J Neuropsychopharmacol. 2002;5:375–88.

    Article  CAS  PubMed  Google Scholar 

  26. Prather AA, Rabinovitz M, Pollock BG, et al. Cytokine-induced depression during IFN- alpha treatment: the role of IL-6 and sleep quality. Brain Behaν Immun. 2009;23:1109–16.

    Article  CAS  Google Scholar 

  27. Hirohata S, et al. NPSLE Research Subcommittee. Accuracy of cerebrospinal fluid IL-6 testing for diagnosis of lupus psychosis. A multicenter retrospective study. Clin Rheumatol. 2009; 28:1319–23.

    Google Scholar 

  28. Yoshio T, et al. IgG anti-NR2 glutamate receptor autoantibodies from patients with systemic lupus erythematosus activate endothelial cells. Arthritis Rheum. 2013;65:457–63.

    Article  CAS  PubMed  Google Scholar 

  29. Lenhoff S, et al. Granulocyte interactions with GM-CSF and G-CSF secretion by endothelial cells and monocytes. Eur Cytokine Netw. 1999;10:525–32.

    CAS  PubMed  Google Scholar 

  30. Cassatella MA, et al. Regulated production of the interferon-gamma-inducible protein-10 (IP-10) chemokine by human neutrophils. Eur J Immunol. 1997;27:111–5.

    Article  CAS  PubMed  Google Scholar 

  31. Deshmane SL, et al. Monocyte Chemoattractant Protein-1 (MCP-1): an overview. J Interf Cytokine Res. 2009;29:313–26.

    Article  CAS  Google Scholar 

  32. Katsumata Y, et al. Diagnostic reliability of cerebral spinal fluid tests for acute confusional state (delirium) in patients with systemic lupus erythematosus: interleukin 6 (IL-6), IL-8, interferon-alpha, IgG index, and Q-albumin. J Rheumatol. 2007;34:2010–7.

    CAS  PubMed  Google Scholar 

  33. George-Chandy A, et al. Raised intrathecal levels of APRIL and BAFF in patients with systemic lupus erythematosus: relationship to neuropsychiatric symptoms. Arthritis Res Ther. 2008;10:R97.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Hirohata S, et al. Clinical characteristics of neuro-Behcet’s disease in Japan: a multicenter retrospective analysis. Mod Rheumatol. 2012;22:405–13.

    Article  PubMed  Google Scholar 

  35. Fujita Y, et al. Aseptic meningitis in mixed connective tissue disease: cytokine and anti-U1RNP antibodies in cerebrospinal fluids from two different cases. Mod Rheumatol. 2008;18:184–8.

    Article  PubMed  Google Scholar 

  36. Matsushita T, et al. Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis. PLoS One. 2013;8:e61835.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Schneider A, et al. The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. J Clin Invest. 2005;115:2083–98.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Pitzer C, et al. Granulocyte-colony stimulating factor improves outcome in a mouse model of amyotrophic lateral sclerosis. Brain. 2008;131(Pt 12):3335–47.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med. 2006;354:610–21.

    Article  CAS  PubMed  Google Scholar 

  40. Iwamoto T, et al. Molecular aspects of rheumatoid arthritis: chemokines in the joints of patients. FEBS J. 2008;275:4448–55.

    Article  CAS  PubMed  Google Scholar 

  41. Luster GS. Mechanisms of disease: chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med. 1998;338:436–45.

    Article  CAS  PubMed  Google Scholar 

  42. Bazan JF, et al. A new class of membrane-bound chemokine with a CX3C motif. Nature. 1997;385:640–4.

    Article  CAS  PubMed  Google Scholar 

  43. Yajima N, et al. Elevated levels of soluble fractalkine in active systemic lupus erythematosus: potential involvement in neuropsychiatric manifestations. Arthritis Rheum. 2005;52:1670–5.

    Article  CAS  PubMed  Google Scholar 

  44. Sato E, et al. Soluble fractalkine in the cerebrospinal fluid of patients with neuropsychiatric lupus. Ann Rheum Dis. 2006;65:1257–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Schall TJ, et al. Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature. 1990;347:669–71.

    Article  CAS  PubMed  Google Scholar 

  46. Vierboom MP, et al. Inhibition of the development of collagen-induced arthritis in rhesus monkeys by a small molecular weight antagonist of CCR5. Arthritis Rheum. 2005;52:627–36.

    Article  CAS  PubMed  Google Scholar 

  47. Okamoto H, Kamatani N. A CCR-5 antagonist inhibits the development of adjuvant arthritis in rats. Rheumatology. 2006;45(2):230.

    Article  CAS  PubMed  Google Scholar 

  48. Moser B, Loetscher P. Lymphocyte traffic control by chemokines. Nat Immunol. 2001;2:123–8.

    Article  CAS  PubMed  Google Scholar 

  49. Baggiolini M, et al. Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils. J Clin Invest. 1989;84:1045–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Bromley SK, et al. Orchestrating the orchestrators: chemokines in control of T cell traffic. Nat Immunol. 2008;9:970–80.

    Article  CAS  PubMed  Google Scholar 

  51. Stievano L, et al. C and CX3C chemokines: cell sources and physiopathological implications. Crit Rev Immunol. 2004;24:205–28.

    Article  CAS  PubMed  Google Scholar 

  52. Murphy G, et al. Fractalkine in rheumatoid arthritis: a review to date. Rheumatology. 2008;47:1446–51.

    Article  CAS  PubMed  Google Scholar 

  53. Sato W, et al. Human Th17 cells are identified as bearing CCR2+CCR5- phenotype. J Immunol. 2007;178:7525–9.

    Article  CAS  PubMed  Google Scholar 

  54. Okamoto H, et al. Molecular aspects of rheumatoid arthritis: role of transcription factors. FEBS J. 2008;275:4463–70.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Rheumatology and Clinical Immunology, School of Medicine, Jichi Medical University, Shimotsuke-shi, Tochigi, Japan

    Taku Yoshio

  2. Minami-otsuka institute of technology, Minami-otsuka Clinic, Tokyo, Japan

    Hiroshi Okamoto

Authors
  1. Taku Yoshio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiroshi Okamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Taku Yoshio .

Editor information

Editors and Affiliations

  1. Department of Rheumatology, Nobubara Hospital, Tatsuno, Hyogo, Japan

    Shunsei Hirohata

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Yoshio, T., Okamoto, H. (2018). Cytokines and Chemokines. In: Hirohata, S. (eds) Neuropsychiatric Systemic Lupus Erythematosus. Springer, Cham. https://doi.org/10.1007/978-3-319-76496-2_6

Download citation

Publish with us

Policies and ethics

Search

Navigation